and distal metastasis. 4 The mechanisms related to HCC tumorigenesis still remain poor understood. Therefore, identifying novel therapeutic targets is strongly required for developing diagnostic markers and effective therapeutics for HCC patients.
The non-coding RNA emerges as an essential regulator in various pathways. 5 Notably, the long non-coding RNAs (lncRNAs) are noncoding RNAs longer than 200 nucleotides with no or minimal protein coding abilities. 6 LncRNAs can actively participate in several biological processes including embryonic stem cell differentiation, senescence, autophagy, apoptosis, and multi-drug resistance [7] [8] [9] via cis-or trans-regulation. 10 Furthermore, lncRNAs can interact with proteins or mRNAs to exert their biological functions. 11, 12 Tissue-specific and frequently dysregulated expression can usually be observed for ln-cRNAs in various cancers with significant correlation to recurrence and poor prognosis. 13 For example, lncRNA-NEF represses epithelial to mesenchymal transition (EMT) by decreasing FOXA2 expression and inactivating Wnt/β-catenin pathway. 14 HNF1A-AS1, which is transcriptionally upregulated by HNF1α, can suppress HCC malignancy by enhancing SHP-1 activity. 15 Instead, lncRNA HOXA11-AS can serve as competing endogenous RNA to lower miR-214-3p levels and promote HCC progression. 16 Therefore, the exact role of ln-cRNAs in cancers is highly complex, depending on the circumstance.
In current work, we reported a novel intergenic lncRNA RP11-279F6.2 (ENSG00000259457), which we termed tumorigenic lncRNA on chromosome 15 (TGLC15), can serve a putative tumorigenic factor during HCC progression. TGLC15 was frequently upregulated in HCC samples and various HCC cell lines. Increasing TGLC15 levels promoted malignant phenotypes of HCC cells in vitro. Silencing TGLC15 expression consistently inhibited xenograft tumor growth in vivo. Mechanistic investigation showed identified transcription factor Sox4 as the TGLC15 binding partner. Interaction between TGLC15 and Sox4 reduced Sox4 turnover by lowering ubiquitin-mediated proteasome degradation. Taken together, we have demonstrated that TGLC15 could serve as an oncogenic lncRNA in HCC by stabilizing Sox4. Our findings may therefore provide novel insight into the strategies for eradicating liver cancer cells.
| MATERIAL S AND ME THODS

| Cell culture and reagents
All cell lines HCC-LM3, 97L, Huh7, HepG2, Hep3B, and the normal L02 cell line were purchased from Shanghai Cell Biology Institute.
Dulbecco's modified Eagle's medium (DMEM) with 8% fetal bovine serum (FBS), 100 μg/mL penicillin, 100 U/mL streptomycin, and 150 μg/mL streptomycin (Sigma) was used for cell culture with an atmosphere of 5% CO 2 in an incubator at 37°C. Reagent details were listed in Table S1.
| Human samples
The HCC samples were surgical archives at The Seventh Affiliated Hospital, Sun Yat-sen University from August 2017 to May 2018.
Formal written consent was obtained from all patients. After treatment by liquid nitrogen, all HCC samples were stored at the −80°C refrigerator. Experimental procedures related to human samples were formally approved by Human Research Ethics Committee at The Seventh Affiliated Hospital, Sun Yat-sen University.
| Lentiviral construction
The TGLC15 sequences were amplified and then cloned into the pWPXL vector. The lentiviral constructs were obtained from Life Technologies (Shanghai). An empty lentiviral vector was used as overexpression control. The short hairpin RNA (ShRNA) targeting TGLC15 and Sox4 was designed by Life Technologies (Shanghai). A scramble RNA was designed as the control. Transfection was performed with Lipofectamine 2000 system (Invitrogen) at the presence of 2 μg/mL polybrene (Sigma). The sequence details were listed in Table S1.
| Migration assay
Migration was evaluated by the Transwell chemotaxis 24-well chamber (BD Biosciences). 2 × 10 5 cells were placed in the upper chamber with non-coated membranes. After an incubation for 24 hours, cells migrating into lower chambers were fixed in paraformaldehyde (3%, Sigma) and stained with crystal violet (0.4%, Sigma). An invert microscope (Olympus) was used to visualize the data.
| Statistical analysis
Statistics were identified using SPSS (version 15, SPSS, Inc). Data were represented as mean ± SD. Mann-Whitney test was used for comparison between two groups, and ANOVA was performed for multiple group comparison followed by LSD post hoc test. Three replicates were done at least. P < .05 was statistically significant.
| RE SULTS
| TGLC15 is an HCC related lncRNA
Previous report has identified multiple novel lncRNAs implicated in cancer progression. 17 Since lncRNAs may play complex regulation depending on cellular content, 18 we therefore screened for potentially oncogenic factors involved in HCC development. Profiling was performed for 370 potential lncRNAs between HCC and normal adjacent tissues (NATs) ( Figure 1A ). As a result, 33 aberrantly upregulated ones were uncovered ( Figure 1B ). Volcano plot showed that the lncRNA RP11-279F6.2 (TGLC15) was the highest upregulated one ( Figure 1C ). We therefore chose TGLC15 for further analysis. TGLC15 had a dominant 1068-nt transcript and transcript analysis with Coding Potential Assessment Tool (CPAT) suggested that TGLC15 had minimal coding potential (Figures S1A and Figure   S1C ). Furthermore, Coding Potential Calculator (CPC) also suggested that TGLC15 had limited coding potential (score 0.224 compared with 12.246 for GAPDH, http://cpc.cbi.pku.edu.cn/). Northern blot showed that TGLC15 was evidently expressed in selected HCC cell lines with highest expression in HCC-LM3 cells ( Figure S1B ). TGLC15 was significantly upregulated in HCC tissues compared with normal ones ( Figure 1D ). Higher TGLC15 expression significantly correlated with advanced TNM stage, metastasis, or tumor size, whereas age and gender did not display significant correlation with TGLC15 (Table S2) . Consistently, TGLC15 level was also increased in HCC cell lines ( Figure 1E ). Subcellular fractionation assays argued that TGLC15 predominantly located in nucleus ( Figure 1F ). Furthermore, fluorescence in situ hybridization (FISH) also confirmed a dominantly nuclear distribution for TGLC15 ( Figure 1G ). These data suggested that TGLC15 was upregulated in HCC with dominant localization in nucleus.
| TGLC15 promotes HCC malignancy in vitro
To further investigate the function of TGLC15, we performed several in vitro experiments. We first verified the overexpression and knockdown efficiency for TGLC15 (Figure 2A,B ). We found that TGLC15 overexpression significantly elevated TGLC15 expression in HCC-LM3 and HepG2 cells (Figure 2A ). Consistently, silencing by shRNA markedly knocked down TGLC15 levels in HCC-LM3 and HepG2 cells ( Figure 2B ). Overexpressing TGLC15 markedly 
| TGLC15 promotes tumor growth in vivo
We then evaluated whether TGLC15 displayed oncogenic function in vivo. Transplantation studies were performed. We found that the increase in tumor volumes was accelerated by TGLC15 overexpression ( Figure 3A) . Meanwhile, silencing TGLC15 decreased xenograft tumor growth ( Figure 3A) . The mouse body weight was not affected by TGLC15 silence or overexpression ( Figure 3B ). Representative images for xenograft tumors were shown ( Figure 3C,D) . The results further confirmed that TGLC15 overexpression significantly increased tumor growth, whereas TGLC15 knockdown played an inhibitory role (Figure 3C,D) . The Ki-67 staining showed that TGLC15 depletion significantly decreased positive fractions, while TGLC15 overexpression promoted HCC proliferation ( Figure 3E ). There data collectively consolidated an oncogenic role for TGLC15 in vivo.
| TGLC15 interacts with Sox4
To further explore the mechanisms of TGLC15 during HCC progression, we performed RNA pulldown assays. Experiments showed one specific band around 50 kD ( Figure 4A ). This band was then sent for mass spectrometry analysis, and the results suggested five putative binding proteins (Table S3 ). Immunoblots confirmed Sox4 as the TGLC15 binding partner ( Figure 4B ). Furthermore, RNA immunoprecipitation (RIP) showed that TGLC15 was consistently enriched in Sox4 pulldowns using antibody against Sox4 ( Figure 4C ). Several TGLC15 mutants were constructed to identify the binding domains of TGLC15 to Sox4. The results showed that the central 268-722 nt fragment was responsible for the interaction with Sox4 ( Figure 4D ).
Competitive binding assays again confirmed the interaction between TGLC15 and Sox4 ( Figure 4E ). Since Sox4 served as the binding protein for TGLC15, we then investigated whether silencing Sox4 had an effect on HCC progression. As expected, Sox4 knockdown lowered the migration of HepG2 cells, while Sox4 overexpression F I G U R E 2 TGLC15 promotes HCC progression in vitro. A, HepG2 and HCC-LM3 cells were transfected with empty lentiviral vectors or vectors containing TGLC15. B, HCC-LM3 and HepG2 cells were transfected with either scramble control or shRNA targeting TGLC15. ShTGLC15#1 (Sh#1) was chosen owing to higher efficiency. C, D, Cell viability assays for HCC-LM3 (C) and HepG2 cells (D) with TGLC15 silence or overexpression. E, Migratory ability for HCC-LM3 and HepG2 cells transfected with lentiviral control vector (control), lentiviral vector with TGLC15 (TGLC15), scramble control shRNA (ShCtrl), or shRNA for TGLC15 (ShTGLC15). (F) Quantification of migration assays for (E). **: P < .01 enhanced HepG2 migration ( Figure 4F,G) . These results demonstrated that TGLC15 interacted with Sox4 through its central domain to promote HCC development.
| TGLC15 binding inhibits degradation of Sox4
The changes in Sox4 might occur at transcript or protein levels. Therefore, we quantified mRNA expression of Sox4 with altered TGLC15 expression. Results showed that alterations in TGLC15 levels did not affect Sox4 transcripts ( Figure 5A ). However, TGLC15 depletion significantly decreased the abundance of Sox4 proteins ( Figure 5B,C) . Moreover, treatment with proteasome inhibitor MG132 strongly reversed the effect of TGLC15 knockdown ( Figure 5B,C) . We then sought to determine whether TGLC15 affected Sox4 ubiquitination. Not surprisingly, TGLC15 overexpression markedly reduced the ubiquitin ligation to Sox4, while TGLC15 silence could strengthen Sox4 ubiquitination ( Figure 5D ). As demonstrated above, increasing TGLC15 expression increased HepG2 cell migration, whereas depleting Sox4 reduced the migration of HepG2 cells ( Figure 5E ). However, combined TGLC15 overexpression and Sox4 silence also inhibited the migration of HepG2 cells to a similar extent in which only Sox4 was knocked down ( Figure 5E ). The results suggested that TGLC15 and Sox4 biding could protect Sox4 from proteasome-mediated degradation leading to increased abundance of Sox4 in HCC. Accumulating data have shown that lncRNAs actively participate in various processes including oncogenesis. 19 Numerous mechanisms have enriched the mode of action of lncRNAs during cancer progression. For instance, lncRNA small nucleolar RNA host gene 3 (SNHG3) has oncogenic potential and induces sorafenib resistance via miR-128/CD151 axis cascade. 20 LncRNA FABP5P3 binds miF-589-5p to upregulate ZMYND19 protein expression and promote HCC progression. 21 A biomarker lncRNA-HEIH is significantly upregulated in serum and exosomes in HCV-related hepatocellular carcinoma. 22 LncRNA-NEF, however, plays a tumor suppressive role by inhibiting epithelial to mesenchymal transition (EMT) as well as metastasis through regulating Wnt/β-catenin pathway. 14 The lncRNA TSLNC8 is also significantly downregulated in HCC and TSLNC8 represses HCC progression by interaction with transketolase (TKT). 23 In current research, we have identified a novel long noncoding RNA termed TGLC15 which is critically involved during HCC progression. Sox4 was shown to be the binding partner of TGLC15 and TGLC15-Sox4 interaction strongly decreased the degradation rate of Sox4. Consequently, we argued that TGLC15 may exert an oncogenic role during HCC development by stabilizing Sox4.
| D ISCUSS I ON
We noticed that TGLC15 could bind Sox4, which is a well-characterized transcription factor and plays important roles especially in tumor progression. 24 During the search for oncogenes, Medina et al 25 found that the Sox4 is usually amplified on chromosome 6 in cancer. Sox4 mutants (S395X) showed enhanced expression owing to the loss of C-terminal degradation domain and promote cancer F I G U R E 4 TGLC15 interacts with Sox4. A, Sense and antisense TGLC15 was subject to RNA pulldowns. The indicated band (arrow) was resected for mass spectrometry (MS). B, Proteins obtained by RNA pulldown were analyzed by antibodies against Sox4. C, RNA immunoprecipitation (RIP) data for TGLC15. **: P < .01. The H19 lncRNA was used as a negative control. D, Wild-type and different TGLC15 truncates were constructed to identify the binding regions of TGLC15 for Sox4. E, Competitive binding assays using biotin labeled (abbreviated as B) and non-biotin labeled TGLC15 (NB) to confirm the interaction between TGLC15 and Sox4. F, Migration assays for HepG2 cells with Sox4 knockdown or overexpression. G, Quantification data for (F). **: P < .01 progression. 26 Sox4 also inhibits p53-induced transcription and suppresses the tumor suppressive activities of p53. 27 Sox4 overexpression induced by STAT3 also enhances the progression of HCC especially in liver tumor-initiating cells (TICs). 28 Notably, there is still a possibility that TGLC15 may behave as a competing endogenous RNA (ceRNA) to promote HCC. For example, lncRNA FLVCRR1-AS1 can sponge miR-513c and induces MET expression in HCC. 31 Whether TGLC15 may interact with other mRNA molecules (eg, through RIP-seq) to exert additional function remains to be determined.
In conclusion, we have demonstrated a novel lncRNA TGLC15 during HCC progression. The interaction between TGLC15 and Sox4 may result in impaired Sox4 ubiquitination and enhanced Sox4 abundance. Hence, TGLC15-Sox4 signaling might shed light on the critical role of TGLC15 and provide a potential target to ameliorate the malignancy during HCC development.
F I G U R E 5 TGLC15 reduces Sox4 degradation. A, Temporal patterns of Sox4 transcripts in HepG2 cells with TGLC15 knockdown or overexpression after blockage of RNA synthesis with α-amanitin (30 μM). The expression was normalized to the value at time 0. ns: Not significant. B, HepG2 cells transfected with ShCtrl, ShTGLC15, empty lentiviral vector (control), or lentiviral vector with TGLC15 (TGLC15) were treated with or without MG132 (20 μM). The immunoblots were used to detect Sox4 expression. C, Quantification of data from (B). The Sox4 expression was normalized to that at time 0. **: P < .01. D, HepG2 lysates with either TGLC15 silence or overexpression were first immunoprecipitated with Sox4 followed by immunoblot toward ubiquitin. GAPDH was used as the control. E, Migration assay in HepG2 cells transfected with ShCtrl, control vector, ShSox4, lentiviral vector containing TGLC15 (TGLC15), or ShSox4 + lentiviral TGLC15 vector (TGLC15 + ShSox4). The knockdown efficiency for Sox4 was shown as an inset panel. Sh#2 was selected for higher efficiency. **: P < .01
